ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Measurement Instrument"

  • Abstract Number: 0207 • ACR Convergence 2022

    Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App

    Valentin Hamy1, Christopher Llop2, Christopher W Yee2, Luis Garcia-Gancedo3, Aoife Maxwell4, Wen-Hung Chen5, Ryan Tomlinson3, Priyanka Bobbili2, Julien Bendelac2, Jessica Landry2, Maral DerSarkissian6, Mihran Yenikomshian2, Elinor A Mody7, Mei Sheng Duh2 and Rachel Williams3, 1GlaxoSmithKline, London, United Kingdom, 2Analysis Group Inc, Boston, MA, 3GlaxoSmithKline, Philadephia, 4GlaxoSmithKline, Stevenage, United Kingdom, 5GlaxoSmithKline, Value Evidence and Outcomes, Philadephia, 6Analysis Group Inc, Los Angeles, CA, 7Reliant Medical Group, Worcester, MA

    Background/Purpose: RA symptoms are typically only assessed intermittently in clinical practice and clinical trials. Digital technologies (wearables, smartphones) can facilitate continuous remote monitoring of patients'…
  • Abstract Number: 0269 • ACR Convergence 2022

    Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage

    Marijke van den Dikkenberg1, Martijn Kuijper2, Marc Kok1, Deirisa Lopes Barreto2 and Angelique Weel1, 1Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, 2Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam

    Background/Purpose: In modern Rheumatoid Arthritis (RA) care remote consults (via phone or video call) are increasing. Whereas the Disease Activity Scores (DAS) requires a patient…
  • Abstract Number: 0571 • ACR Convergence 2022

    National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results

    Anna Montgomery1, Gary Tarasovsky2, Mary Whooley2, Jennifer Barton3, Karla Miller4, Holly Mitchell5, Jo Dana2, Kimberly Reiter6, Elizabeth Wahl7, Karine Rozenberg-Ben-Dror8, Jing Li9 and Gabriela Schmajuk10, 1University of California San Francisco, Reno, NV, 2San Francisco VA Medical Center, San Francisco, CA, 3VA Portland Health Care System/OHSU, Portland, OR, 4University of Utah Division of Rheumatology/VA Salt Lake City Health Care, Salt Lake City, UT, 5Ralph H. Johnson VA Hospital, Mount Pleasant, SC, 6Albuquerque VA Medical Center, Albuquerque, NM, 7VA Puget Sound Healthcare System, Seattle, WA, 8Greater Lakes Region/VISN 12 Dept Veterans Affairs, Hines, IL, 9University of California, San Francisco, San Francisco, CA, 10UCSF / SFVA, San Francisco, CA

    Background/Purpose: Guidelines recommend testing for latent hepatitis B virus (HBV), hepatitis C virus (HCV), and tuberculosis (TB) infection prior to initiating biologics or targeted synthetic…
  • Abstract Number: 0803 • ACR Convergence 2022

    Performance of Adenosine Deaminase Activity in Sinovial Fluid for the Early Diagnosis of Tuberculous Arthritis: A Meta Analysis

    Juan Carlos Cortés-Quiroz1, Javier Ena2, José Antonio Bernal3 and José Rosas4, 1Marina Baixa Hospital, Mutxamel, Spain, 2Department of Internal Medicine. Marina Baixa Hospital, Villajoyosa, Spain, 3Rheumatology Department. Marina Baixa Hospital, Alicante, Spain, 4Rheumatology Department, Hospital Marina Baixa, Villajoyosa, Spain

    Background/Purpose: Adenosine deaminase (ADA) activity has shown good performance in diagnosing pleural, peritoneal, and meningeal tuberculosis. This study aimed to evaluate the performance of measuring…
  • Abstract Number: 1013 • ACR Convergence 2022

    Discriminatory Capacity of the ASAS Health Index in Patients with Axial Spondyloarthritis Treated in a Tight Control Setting versus Standard of Care

    Uta Kiltz1, Anna Molto2, Clementina Lopez-Medina3, Maxime Dougados4, Désirée van der Heijde5, Annelies Boonen6, Filip Van den bosch7 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumatology Department, Cochin Hospital, APHP, Paris, France, 3Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, 4Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, 5Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 6Maastricht University Medical Centre, Maastricht, Netherlands, 7Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium

    Background/Purpose: Improvement in functioning and health as assessed by the ASAS Health Index (HI) is an important outcome of interventions in patients with axial spondyloarthritis…
  • Abstract Number: 1232 • ACR Convergence 2022

    Reliability and Validity of Single Axial Slice vs. Multiple Slice Quantitative Measurement of the Volume of Effusion-Synovitis on 3T Knee MRI in Knees with Osteoarthritis

    Greg Gilles1, Arjun Vohra1, Chelsea Caruso1, Dagoberto Robles1, Mihra Taljanovic1, Jeffrey Duryea2, Erin Ashbeck1, Edward Bedrick3 and Kent Kwoh4, 1University of Arizona Arthritis Center, Tucson, AZ, 2Brigham and Women's Hospital, Boston, MA, 3Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, 4University of Arizona, Tucson, AZ

    Background/Purpose: Effusion-synovitis (ES) on knee MRI has been identified as an important biomarker of OA. Semi-automated software methods offer objective measurements of ES volume on…
  • Abstract Number: 1246 • ACR Convergence 2022

    Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis

    Michal Cidon1, Beverley Newman2, Terry Robinson3, Paul Iskander4, Paul Thacker5, Evan Zucker2, Tzielan Lee6 and Rex Moats3, 1Children's Hospital Los Angeles, Los Angeles, CA, 2Stanford Children's Health, Stanford, CA, 3Children's Hospital of Los Angeles, Los Angeles, CA, 4University of California Los Angeles, Los Angeles, CA, 5Mayo Clinic, Rochester, MN, 6Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: We presented preliminary data in 2021 to support the feasibility of using a semi-quantitative chest CT scoring system (Pediatric Rheumatologic Diffuse Lung Disease Score…
  • Abstract Number: 1366 • ACR Convergence 2022

    Developing a Mobile App to Facilitate Disease Activity Assessment in Localized Scleroderma

    Suzanne Li1, Xiaohu Li2, Tara Lozy3 and Jiajun Chen4, 1Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, 2Stevens Institute of Technology, Hoboken, NJ, 3Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 4One Node Lab, League City, TX

    Background/Purpose: Juvenile localized scleroderma (jLS) is an inflammatory and fibrosing disease that causes severe morbidity (e.g., hemiatrophy, arthropathy, seizures), with functional impairment found in >25%…
  • Abstract Number: 2054 • ACR Convergence 2022

    Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process

    Kathryn Connelly1, Laura Eades2, Rachel Koelmeyer3, Darshini Ayton3, Vera Golder2, Rangi Kandane-Rathnayake2, Kate Gregory-Wong3, Hussein Al-Mossawi4, Jeanette Andersen5, Cynthia Aranow6, Laurent Arnaud7, Anca Askanase8, Subhashis Banerjee9, Catherine Barbey10, Hermine Brunner11, Joy Buie12, Laurie Burke13, Alain Cornet14, Karen Costenbader15, Maria Dall'Era16, Khadija Dantata17, Nikolay Delev9, Ann Eldred18, Alan Friedman19, Richard Furie20, Sandra Garces21, Dennis Grasela22, Heath Guay23, Oliver Guenther24, Maria Juarez25, Shelly Kafka26, Kenneth Kalunian27, Elaine Karis28, Youmna Lahoud29, Catharina Lindholm30, Jeffrey Lockman31, Charlotte Lupton32, Justine Maller33, Ashley Marion34, Patrick Marquis35, Joan Merrill36, Thomas Morel37, Marta Mosca38, Yulia Pincus39, Samantha Pomponi40, Guillermo Pons-Estel41, Jorge Ross Terres33, Cailin Sibley42, Maria Silk43, Sanjeev Roy44, Lee S Simon45, Alessandro Sorrentino46, Christian Stach47, George Stojan48, Ying Sun24, Yoshiya Tanaka49, Erik Thomas50, Ronald van Vollenhoven51, Cristina Vazquez Mateo50, Edward M Vital52, Victoria Werth53, Eric Zollars28, Qing Zuraw54 and Eric Morand55, 1Monash Health, Camberwell, Australia, 2Monash University, Clayton, Australia, 3Monash University, Melbourne, Australia, 4AstraZeneca, Bucks, United Kingdom, 5Lupus Europe, Lupus DK, EULAR PARE, ERN ReCONNECT, Brussels, Belgium, 6Feinstein Institutes for Medical Research, Manhasset, NY, 7Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France, 8Columbia University Medical Center, New York, NY, 9Bristol Myers Squibb, Princeton, NJ, 10Biogen, Baar, Switzerland, 11Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, 12Lupus Foundation of America, Charleston, SC, 13LORA Group, Royal Oak, MD, 14Lupus Europe, Brussels, Belgium, 15Brigham and Women's Hospital, Boston, MA, 16University of California, Division of Rheumatology, San Francisco, CA, 17Lupus Foundation of America, Richmond Hill, GA, 18AbbVie, Inc., Lake Bluff, IL, 19AbbVie, Inc., Libertyville, IL, 20Northwell Health, Great Neck, NY, 21Amgen, Inc., Almada, Portugal, 22Bristol Myers Squibb, Lawrencevile, NJ, 23AbbVie, Inc., Worcester, MA, 24Merck KGaA, Darmstadt, Germany, 25UCB Pharma, Slough, United Kingdom, 26AbbVie, Inc., Norristown, PA, 27University of California San Diego, La Jolla, CA, 28Amgen, Inc., Thousand Oaks, CA, 29Biogen International GmbH, Milton, MA, 30AstraZeneca, Gothenburg, Sweden, 31Bristol-Myers Squibb, New York, NY, 32AstraZeneca, Cambridge, United Kingdom, 33Genentech, San Francisco, CA, 34Lupus Foundation of America, Washington, DC, 35Modus Outcomes, Cambridge, MA, 36Oklahoma Medical Research Foundation, Oklahoma City, OK, 37UCB Pharma, Brussels, Belgium, 38University of Pisa, Pisa, Italy, 39Janssen, Flemington, NJ, 40Bristol Myers Squibb, Lawrence Township, NJ, 41Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, 42Janssen Research & Development, San Diego, CA, 43Eli Lilly, Carmel, IN, 44Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany,45SDG LLC, West Newton, MA,46AstraZeneca, Sollentuna, Sweden, 47UCB Pharma, Monheim, 48UCB Pharma, Baltimore, MD, 49University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 50EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, 51Amsterdam University Medical Centers, Amsterdam, Netherlands, 52Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 53University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 54Janssen Research and Development, LLC, Spring House, PA, 55Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia

    Background/Purpose: Most late-phase randomised controlled trials (RCTs) of novel drugs for systemic lupus erythematosus (SLE) have failed to meet their primary endpoint or shown contradictory…
  • Abstract Number: 2058 • ACR Convergence 2022

    Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus

    Stefan Perera1, Jiandong Su2, Kathleen Bingham3, Mahta Kakvan1, Maria Carmela Tartaglia4, Leslet Ruttan5, Joan Wither1, May Choi6, Simone Appenzeller7, Dorcas Beaton8, Dennisse Bonilla2, Patricia Katz9, Robin Green5, Michelle Barraclough10 and Zahi Touma2, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 3Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 4University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, 5University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, 6Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 7Unicamp, Campinas, São Paulo, Brazil, 8Institute for Work & Health, Toronto, ON, Canada, 9UCSF, San Rafael, CA, 10Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada

    Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…
  • Abstract Number: 2142 • ACR Convergence 2022

    Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial

    William Tillett1, Laura Coates2, Mohamed Sharaf3, Marlies Neuhold4, Elke Theander5, Paul Bergmans6, May Shawi7, Michelle Perate8, Christine Contré9 and Philip Helliwell10, 1Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, 5Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, 6Formerly at Janssen, Breda, Netherlands, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Janssen Scientific Affairs, LLC, Horsham, PA, 9Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 10Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Accurate assessment of psoriatic arthritis (PsA) disease activity in clinical practice requires a feasible, continuous, multidimensional composite instrument to assess key domains of this…
  • Abstract Number: 1731 • ACR Convergence 2021

    Construction and Validation of a Reproductive Health Questionnaire for Women with Rheumatic Diseases

    Abraham Yair Lujano-Negrete1, Luz Ferandanda Gutierrez-Leal2, Luis Gerardo Espinosa-Banuelos3, Cassandra Michele Skinner-Taylor1, Lorena Perez-Barbosa4, Ingris Peláez-Ballestas5, Eugenio Salvador Barriga-Maldonado6, Martha Cecilia Rodriguez-Ruiz1, Sofía Jezzini-Martínez1, Selene Maribel Delgado-Ayala1, Jesus Cardenas-de La Garza4 and Dionicio Galarza-Delgado4, 1Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, 2Universidad Autónoma de Nuevo León, Monterrey, Mexico, 3Faculty of Medicine and University Hospital Dr. Jose Eleuterio Gonzalez, UANL, Monterrey, Mexico, 4Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, 5Hospital General de Mexico "Dr. Eduardo Liceaga", Mexico, Mexico, 6Hopsital Universitario Dr. José Eleuterio González, Monterrey, Mexico

    Background/Purpose: Autoimmune rheumatic diseases (ARDs) commonly affect women of childbearing age. Active maternal disease in the months prior to conception increases the risk of flares…
  • Abstract Number: 1893 • ACR Convergence 2021

    “From Where I Stand”: Using Multiple Anchors Yields Different Benchmarks for Meaningful Improvement and Worsening in the Rheumatoid Arthritis Flare Questionnaire (RA-FQ)

    Susan Bartlett1, Vivian Bykerk2, Orit Schieir3, Marie-France Valois1, Louis Bessette4, Gilles Boire5, Glen Hazlewood6, Carol Hitchon7, Edward Keystone8, Janet Pope9, Diane Tin10, Carter Thorne11, Clifton Bingham12 and CATCH Investigators13, 1McGill University, Montréal, QC, Canada, 2Hospital for Special Surgery, New York, NY, 3Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 4Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 5Universite de Sherbrooke, Sherbrooke, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 9University of Western Ontario, London, ON, Canada, 10The Arthritis Program Research Group, Newmarket, ON, Canada, 11Southlake Regional Health Centre, Newmarket, ON, Canada, 12Johns Hopkins University, Baltimore, MD, 13Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada

    Background/Purpose: The RA-FQ is a patient-reported measure of current disease activity in RA that can be used to identify disease flares. The RA-FQ queries pain,…
  • Abstract Number: 0176 • ACR Convergence 2021

    Semi-quantitative Chest Computed Tomography (CT) Analysis in Pediatric Rheumatologic (PR) Patients with Diffuse Lung Disease

    Michal Cidon1, Terry Robinson2, Beverley Newman3, Paul Iskander2, Paul Thacker4, Evan Zucker3, Brian Bartholmai4, Dnyanesh Tipre2, Tzielan Lee5, Rajdeep Pooni6 and Rex Moats2, 1Children's Hospital Los Angeles, Los Angeles, CA, 2Children's Hospital of Los Angeles, Los Angeles, CA, 3Stanford Children's Health, Stanford, 4Mayo Clinic, Rochester, MN, 5Stanford University School of Medicine, Palo Alto, CA, 6Stanford Children's Health, Palo Alto, CA

    Background/Purpose: Spiral chest CT (SCT) is commonly used to evaluate subclinical lung disease in pediatric rheumatology. However, there are no validated scoring tools to objectively…
  • Abstract Number: 0251 • ACR Convergence 2021

    A Comparative Study of the Validity of the DAS28-ESR and JADAS-27 Disease Activity Assessment Indexes for Juvenile Idiopathic Arthritis in Transition and Adults

    Takako Miyamae1, Eiichi Tanaka1, Eisuke Inoue2, Katsunori Ikari1 and Masayoshi Harigai3, 1Tokyo Women's Medical University, Tokyo, Japan, 2Showa University, Tokyo, Japan, 3Tokyo Women's Medical University School of Medicine, Tokyo, Japan

    Background/Purpose: The 2020 Rheumatoid Arthritis Clinical Practice Guidelines by the Ministry of Health, Labour, and Welfare Research Group recommends the JADAS27 as a measure of…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences